Terms: = Skin cancer AND TRA
12 results:
1. High-throughput RNA sequencing of the T cell receptor alpha and beta chains for simultaneous clonality and biological analyses in Sezary syndrome.
Blanco G; López-Aventín D; Pujol RM; Gómez-Llonín A; Puiggros A; López-Sánchez M; Estrach T; García-Muret MP; López-Lerma I; Servitje O; Bellosillo B; Muro M; Espinet B; Rabionet R; Gallardo F
J Clin Lab Anal; 2023 Dec; 37(23-24):e24982. PubMed ID: 38115685
[TBL] [Abstract] [Full Text] [Related]
2. [Surgical treatment of patients with chest malignancies in anti-tuberculosis hospital].
Nekrasov EV; Sinitsyn MV; Didenko GV; Vorobev AA; Ivanova DA
Khirurgiia (Mosk); 2023; (7):12-19. PubMed ID: 37379401
[TBL] [Abstract] [Full Text] [Related]
3. Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective.
Halloush S; Alkhatib NS; Almutairi AR; Calamia M; Halawah H; Obeng-Kusi M; Hoyle M; Rashdan O; Koeller J; Abraham I
Ann Pharmacother; 2023 Sep; 57(9):1016-1024. PubMed ID: 36639851
[TBL] [Abstract] [Full Text] [Related]
4. KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma.
Zhang H; Liu X; Chen Y; Xu R; He S
Biomed Res Int; 2022; 2022():1556485. PubMed ID: 36212716
[TBL] [Abstract] [Full Text] [Related]
5. A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.
Xie T; Huang CY; Kang X; Luo JS; Qin XM; Han F
J Cell Biochem; 2018 Jan; 119(1):640-649. PubMed ID: 28628251
[TBL] [Abstract] [Full Text] [Related]
6. The Construction and Identification of Induced Pluripotent Stem Cells Derived from Acute Myelogenous Leukemia Cells.
Zhu LF; Chen QR; Chen SZ; Wang LY; Luo XF; Ren JH; Yuan XH; Wu XQ; Zeng YL; Xiao M; Chen YQ; Chen YY; Lin MH; Wu ZJ; Chen ZZ; Hu JD; Yang T
Cell Physiol Biochem; 2017; 41(4):1661-1674. PubMed ID: 28359056
[TBL] [Abstract] [Full Text] [Related]
7. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277
[TBL] [Abstract] [Full Text] [Related]
8. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
[TBL] [Abstract] [Full Text] [Related]
9. Nuclear reprogramming with a non-integrating human RNA virus.
Driscoll CB; Tonne JM; El Khatib M; Cattaneo R; Ikeda Y; Devaux P
Stem Cell Res Ther; 2015 Mar; 6(1):48. PubMed ID: 25889591
[TBL] [Abstract] [Full Text] [Related]
10. [Tumor rejection antigen and cancer immunotherapy].
Matsutake T; Nakayama E
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1871-7. PubMed ID: 7487115
[TBL] [Abstract] [Full Text] [Related]
11. trans-retinoic acid and related differentiation agents.
Parkinson DR; Smith MA; Cheson BD; Stevenson HC; Friedman MA
Semin Oncol; 1992 Dec; 19(6):734-41. PubMed ID: 1462170
[TBL] [Abstract] [Full Text] [Related]
12. A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia.
Meyskens FL; Graham V; Chvapil M; Dorr RT; Alberts DS; Surwit EA
J Natl Cancer Inst; 1983 Nov; 71(5):921-5. PubMed ID: 6580493
[TBL] [Abstract] [Full Text] [Related]
